A Systematic Literature Review of Health Economic Models Structures for Chronic Rhinosinusitis with Nasal Polyps
Author(s)
Pankaj Rai, MS Pharm1, Sumeet Attri, M Pharm1, Barinder Singh, RPh2, Ritesh Dubey, PharmD1, Gagandeep Kaur, M Pharm1;
1Pharmacoevidence, SAS Nagar Mohali, India, 2Pharmacoevidence, London, United Kingdom
1Pharmacoevidence, SAS Nagar Mohali, India, 2Pharmacoevidence, London, United Kingdom
Presentation Documents
OBJECTIVES: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a prevalent inflammatory disease affecting the sinuses and nasal cavity. Economic evaluations (EE) and Health technology assessments (HTAs) are crucial in informing healthcare decisions. The objective of the study is to understand the economic model structure utilized globally in the published EE of adult patients with CRSwNP
METHODS: Key biomedical databases (Embase® and PubMed®) and global HTAs were searched from database inception to December 2024 to identify all published relevant EEs conducted in CRSwNP. Adhering to PRISMA guidelines, two independent reviewers performed screening and data collection, followed by a quality check by a third reviewer
RESULTS: A total of 13 studies (12 EE [7 cost-utility, 5 cost-effectiveness] and 1 HTA) met the inclusion criteria. The studies evaluated biologics (dupilumab, omalizumab, mepolizumab) and surgical interventions (elective sinus surgery, ESS + endoscopic frontal sinusotomy, endoscopic polypectomy in clinic) from the perspective of third-party payers in the US (7), Canada (4), Colombia (1), and Italy (1). The time horizon across studies ranged between 5-36 years, with some studies adopting a lifetime perspective. Cycle lengths varied between 6-24 months, and discount rates ranged from 1.5%-5%. Most EE used a mixed model approach, such as Markov-decision tree analysis, with one study employing a Markov model. Markov models typically utilized 2 to 10 health states, with "responders" and "non-responders" being among the most commonly utilized health states
CONCLUSIONS: This review highlights the predominance of mixed model structures, particularly Markov-decision tree analyses, in evaluating the economic implications of biologics and surgical interventions for CRSwNP however, further comprehensive studies are needed to validate these findings
METHODS: Key biomedical databases (Embase® and PubMed®) and global HTAs were searched from database inception to December 2024 to identify all published relevant EEs conducted in CRSwNP. Adhering to PRISMA guidelines, two independent reviewers performed screening and data collection, followed by a quality check by a third reviewer
RESULTS: A total of 13 studies (12 EE [7 cost-utility, 5 cost-effectiveness] and 1 HTA) met the inclusion criteria. The studies evaluated biologics (dupilumab, omalizumab, mepolizumab) and surgical interventions (elective sinus surgery, ESS + endoscopic frontal sinusotomy, endoscopic polypectomy in clinic) from the perspective of third-party payers in the US (7), Canada (4), Colombia (1), and Italy (1). The time horizon across studies ranged between 5-36 years, with some studies adopting a lifetime perspective. Cycle lengths varied between 6-24 months, and discount rates ranged from 1.5%-5%. Most EE used a mixed model approach, such as Markov-decision tree analysis, with one study employing a Markov model. Markov models typically utilized 2 to 10 health states, with "responders" and "non-responders" being among the most commonly utilized health states
CONCLUSIONS: This review highlights the predominance of mixed model structures, particularly Markov-decision tree analyses, in evaluating the economic implications of biologics and surgical interventions for CRSwNP however, further comprehensive studies are needed to validate these findings
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE409
Topic
Economic Evaluation
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)